Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Rigo

Showing results (81-90 of 163) with videos related to

Pageof 17
Sort By:
Nucleic Acid Therapeutics|January 18, 2018
Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded RepeatLiande Li, Xiulong Shen, Zhongtian Liu, et al.
Nature Medicine|July 29, 2020
Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten diseaseJessica L Centa, Francine M Jodelka, Anthony J Hinrich, et al.
Nature|April 14, 2017
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2Daniel R Scoles, Pratap Meera, Matthew D Schneider, et al.
Neuron|May 24, 2016
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse ModelKathleen M Schoch, Sarah L DeVos, Rebecca L Miller, et al.
Contemporary Clinical Trials|June 12, 2022
A novel 'social contract' - An attempt to harmonize a sponsor's exploratory research with a clinical study participant's data rightsLaurence Mignon, Kim Doan, Michael Murphy, et al.
The Journal of Clinical Investigation|March 22, 2016
Modulation of LMNA splicing as a strategy to treat prelamin A diseasesJohn M Lee, Chika Nobumori, Yiping Tu, et al.
Nature Medicine|February 6, 2013
Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafnessJennifer J Lentz, Francine M Jodelka, Anthony J Hinrich, et al.
NPJ Precision Oncology|January 12, 2022
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcomaSafiya Khurshid, Matias Montes, Daniel F Comiskey, et al.
Cell Reports|April 28, 2021
Tau seeds are subject to aberrant modifications resulting in distinct signaturesJui-Heng Tseng, Aditi Ajit, Zarin Tabassum, et al.
Molecular Therapy. Nucleic Acids|November 3, 2021
Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophyLinde F Bouwman, Bianca den Hamer, Anita van den Heuvel, et al.
Pageof 17

Showing results (81-90 of 163) with videos related to

Sort By:
Pageof 17
Nucleic Acid Therapeutics|January 18, 2018
Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded RepeatLiande Li, Xiulong Shen, Zhongtian Liu, et al.
Nature Medicine|July 29, 2020
Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten diseaseJessica L Centa, Francine M Jodelka, Anthony J Hinrich, et al.
Nature|April 14, 2017
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2Daniel R Scoles, Pratap Meera, Matthew D Schneider, et al.
Neuron|May 24, 2016
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse ModelKathleen M Schoch, Sarah L DeVos, Rebecca L Miller, et al.
Contemporary Clinical Trials|June 12, 2022
A novel 'social contract' - An attempt to harmonize a sponsor's exploratory research with a clinical study participant's data rightsLaurence Mignon, Kim Doan, Michael Murphy, et al.
The Journal of Clinical Investigation|March 22, 2016
Modulation of LMNA splicing as a strategy to treat prelamin A diseasesJohn M Lee, Chika Nobumori, Yiping Tu, et al.
Nature Medicine|February 6, 2013
Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafnessJennifer J Lentz, Francine M Jodelka, Anthony J Hinrich, et al.
NPJ Precision Oncology|January 12, 2022
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcomaSafiya Khurshid, Matias Montes, Daniel F Comiskey, et al.
Cell Reports|April 28, 2021
Tau seeds are subject to aberrant modifications resulting in distinct signaturesJui-Heng Tseng, Aditi Ajit, Zarin Tabassum, et al.
Molecular Therapy. Nucleic Acids|November 3, 2021
Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophyLinde F Bouwman, Bianca den Hamer, Anita van den Heuvel, et al.
Pageof 17